Rabbit Recombinant Monoclonal CXCR3 antibody. Suitable for IP, WB, IHC-P and reacts with Human, Mouse, Rat, Transfected cell line samples. Cited in 7 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IP | WB | IHC-P | ICC/IF | Flow Cyt (Intra) | |
---|---|---|---|---|---|
Human | Tested | Tested | Tested | Not recommended | Not recommended |
Mouse | Expected | Tested | Not recommended | Not recommended | Not recommended |
Rat | Expected | Tested | Not recommended | Not recommended | Not recommended |
Transfected cell line | Not recommended | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/30 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 | Notes - |
Species Rat | Dilution info 1/1000 | Notes - |
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line | Dilution info 1/500 | Notes IHC application does not react with Mouse and Rat species. |
Species Human | Dilution info 1/500 | Notes IHC application does not react with Mouse and Rat species. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes IHC application does not react with Mouse and Rat species. |
Species Rat | Dilution info - | Notes IHC application does not react with Mouse and Rat species. |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat, Mouse, Transfected cell line | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Transfected cell line | Dilution info - | Notes - |
Isoform 1. Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G-protein signaling pathway (PubMed:12782716). Binds to CCL21. Probably promotes cell chemotaxis response. Upon activation by PF4, induces activated T-lymphocytes migration mediated via downstream Ras/extracellular signal-regulated kinase (ERK) signaling. Isoform 2. Receptor for the C-X-C chemokine CXCL4 and also mediates the inhibitory activities of CXCL9, CXCL10 and CXCL11 on the proliferation, survival and angiogenic activity of human microvascular endothelial cells (HMVEC) through a cAMP-mediated signaling pathway (PubMed:12782716). Does not promote cell chemotaxis respons. Interaction with CXCL4 or CXCL10 leads to activation of the p38MAPK pathway and contributes to inhibition of angiogenesis. Overexpression in renal cancer cells down-regulates expression of the anti-apoptotic protein HMOX1 and promotes apoptosis. Isoform 3. Mediates the activity of CXCL11.
CD183, GPR9, CXCR3, C-X-C chemokine receptor type 3, CXC-R3, CXCR-3, CKR-L2, G protein-coupled receptor 9, Interferon-inducible protein 10 receptor, IP-10 receptor
Rabbit Recombinant Monoclonal CXCR3 antibody. Suitable for IP, WB, IHC-P and reacts with Human, Mouse, Rat, Transfected cell line samples. Cited in 7 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IHC application does not react with Mouse and Rat species.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The chemokine receptor CXCR3 also known as CD183 is a protein that plays an important role in immune responses. This receptor is a part of the G protein-coupled receptor (GPCR) family and weighs approximately 41 kDa. CXCR3 is expressed on activated T cells some B cells natural killer (NK) cells and certain subsets of dendritic cells. Its expression is mostly found in inflamed tissues and in conditions where the immune system is active such as infections or autoimmune diseases.
CXCR3 is involved in directing the migration of immune cells to sites of inflammation. This receptor binds to specific chemokines—CXCL9 CXCL10 and CXCL11—that are produced in response to cytokines like IFN-gamma. CXCR3 does not function as part of a larger protein complex; instead it operates independently facilitating the trafficking and activation of its expressing cells. Its activity is pivotal in immune responses assisting in rapid mobilization and targeting of effector cells to needed areas.
CXCR3 is a component of the chemokine signaling pathway which is important for leukocyte chemotaxis. Within this pathway CXCR3 interacts with other receptors and proteins that modulate immune responses such as CXCR4 and CCR5 which also mediate chemotactic migration of leukocytes. Moreover it plays a role in the Jak-STAT signaling pathway impacting gene transcription and cell survival particularly in response to inflammatory signals.
CXCR3 is closely associated with autoimmune diseases like multiple sclerosis and rheumatoid arthritis due to its role in inflammation and immune cell recruitment. The receptor is also involved in cancer where its dysregulation can impact tumor growth and metastasis. CXCR3 through its interaction with chemokines like CXCL10 can influence the tumor microenvironment by affecting the infiltration and function of immune cells. Understanding these interactions can provide insights into therapeutic strategies targeting CXCR3 in these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
CXCR3 was immunoprecipitated from 0.35 mg HT-29 (human colorectal adenocarcinoma epithelial cell) whole cell lysate 10 ug with ab288437 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab288437 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: HT-29 (human colorectal adenocarcinoma epithelial cell) whole cell lysate 10 ug
Lane 2: ab288437 IP in HT-29 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab288437 in HT-29 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes
All lanes: Immunoprecipitation - Anti-CXCR3 antibody [EPR25373-32] (ab288437)
Predicted band size: 40 kDa
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Exposure time: 3 minutes
All lanes: Western blot - Anti-CXCR3 antibody [EPR25373-32] (ab288437) at 1/1000 dilution
Lane 1: Human tonsil tissue lysate at 20 µg
Lane 2: K-562 (human chronic myelogenous leukemia lymphoblast) whole cell lysate at 20 µg
Lane 3: EL4 (mouse lymphoma T lymphocyte) whole cell lysate at 20 µg
Lane 4: AR42J (rat pancreatic tumor epithelial cell) whole cell lysate at 20 µg
Lane 5: GH3 (rat pituitary gland tumor epithelial cell) whole cell lysate at 20 µg
Lane 6: Mouse thymus tissue lysate at 20 µg
Lane 1: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/2000 dilution
Lanes 2 - 6: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 40 kDa
Observed band size: 46 kDa
CXCR3 was immunoprecipitated from 0.35 mg K-562 (human chronic myelogenous leukemia lymphoblast) whole cell lysate 10 ug with ab288437 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab288437 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: K-562 (human chronic myelogenous leukemia lymphoblast) whole cell lysate 10 ug
Lane 2: ab288437 IP in K-562 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab288437 in K-562 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes
All lanes: Immunoprecipitation - Anti-CXCR3 antibody [EPR25373-32] (ab288437)
Predicted band size: 40 kDa
Immunohistochemical analysis of paraffin-embedded (A) HEK-293T cells labelling CXCR3 with ab288437 at 1/500 (6.04 ug/ml) followed by a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used. Positive staining on (A) HEK-293T cells transfected with a CXCR3 expression vector containing a his tag. No staining on (B) HEK-293T cells transfected with empty vector containing a his tag. The section was incubated with ab288437 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins
Immunohistochemical analysis of paraffin-embedded human large B-cell lymphoma tissue labelling CXCR3 with ab288437 at 1/500 (1.208 ug/ml) followed by a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used. Positive staining on human large B-cell lymphoma (PMID: 10627472). The section was incubated with ab288437 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.
Immunohistochemical analysis of paraffin-embedded Human colon tissue labelling CXCR3 with ab288437 at 1/500 (1.208 ug/ml) followed by a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used. Positive staining on human colon. The section was incubated with ab288437 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Leica DS9800 (Bond®, Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labelling CXCR3 with ab288437 at 1/500 (1.208 ug/ml) followed by a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used. Positive staining on human tonsil (PMID: 10627472). The section was incubated with ab288437 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Leica DS9800 (BOND®, Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com